Gina Mauro

Treatment with abemaciclib and standard endocrine therapy reduced the risk of invasive disease recurrence or death in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

The CAR T-cell therapy elicited a 92% ORR, with high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Regardless of age, Selinexor induced a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.

Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.

“Results from this study suggest that tisotumab vedotin has the potential to be a new therapy for patients with previously treated recurrent and/or metastatic cervical cancer,” said lead study author Robert L. Coleman, MD, FACOG, FACS.

In patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss, ipatasertib combined with abiraterone acetate (Zytiga) plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity.

First-line treatment with the third-generation ALK TKI was also associated with higher overall and intracranial response rates in patients with ALK-positive non–small cell lung cancer.

“With expanding options for patients with advanced RCC, the overall efficacy, safety, and quality of life benefits, as well as individual patient characteristics, are very important considerations when you select appropriate therapy.”

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.

Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.

Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia

First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia.